Insiders Trades
Precigen, Inc. Stock: price and insider trades · United States
1 insider bought €21k of shares over the last 90 days, the latest filed 25 Aug 2026.
Precigen, Inc.: what insiders have been doing
Headquartered in Germantown, United States, Precigen, Inc. belongs to the Healthcare & Pharma sector and traces its origins to 1998. Filings by its managers are published through SEC (Form 4). The last twelve months, up to 18 October 2026, brought 66 filings signed by 17 insiders.
Both sides are active: 1 purchase worth €21k and 18 sales worth €23.0M, from 1 insider and 5 insiders respectively. The net balance comes to €23.0M on the selling side. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Those buying include 1 senior executive. Biggest ticket of the year: €6.7M, sold by Kirk Randal J and made public on 31 March 2026.
The clock since the last published purchase (25 August 2026) now reads 53 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
With 66 filings in twelve months, the company is more active than the median of 22 filings across the 5,458 companies we follow on the same exchange. Over the whole record (from 2016), the tally stands at 21 purchases and 58 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 9.7 m USD and net income at -250.6 m USD.
Other companies in the same sector with recent insider buying flagged by our signals: Anixa Biosciences Inc and Vivos Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
261
Thresholds
n/a
Buy Volume
€40M
21 ops. · all time
Sell Volume
€49M
58 ops. · all time
Who traded when
BuySaleKirk Randal J13 sales
Jeffrey B. Kindler3 sales
Nancy H. Agee3 buys
Rutul R. Shah1 buy2 sales
Harry Thomasian Jr.1 buy1 sale
Phil Tennant1 buy1 sale
Since the insiders bought
- -13.9%Entry US$7.42 · Close 16 Oct 2026 US$6.39
- +145.8%Entry US$3.34 · Close at T+365 US$8.21
- +145.8%Entry US$3.34 · Close at T+365 US$8.21
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$7.20
Analyst consensus
3 analysts1.75/5
US$11.00Target US$13.65(+90%)US$17.95
Income statement
RevenueUS$9.7M
Gross profitUS$4.9M50% margin
EBITDA-US$243.6M-2515% margin
Net income-US$250.6M-184.0% margin
Valuation
P/Book59.0x
Beta0.92
Balance sheet & cash
Market capUS$2.6B
Total debtUS$98.3M
Free Cash Flow-US$89.8M
Debt / Equity226%
Profitability & ownership
ROE-837.1%
ROA-18.1%
% insiders12.6%
% institutions73.1%
Last declaration on 24 September 2026
Declarations261 total
2 shares@ US$0.960.0000% mcap0.0% of flowCommon StockSEC:0000950103-26-014457:2
10,744 shares@ US$4.720.0018% mcap1.9% of flowCommon StockSEC:0000950103-26-014457:0
42,918 shares@ US$2.330.0036% mcap3.7% of flowCommon StockSEC:0000950103-26-014457:1
1 shares@ US$1.210.0000% mcap0.0% of flowCommon StockSEC:0000950103-26-014457:3
185,000 shares@ US$7.440.049% mcap44.3% of flowCommon StockSEC:0000950103-26-013201:0
185,000 shares@ US$7.420.048% mcap100.0% of flowCommon StockSEC144:0001958244-26-000558
20,833 sharesCommon StockSEC:0000950103-26-012870:0
7,500 sharesCommon StockSEC:0000950103-26-012872:2
2,488 shares@ US$7.200.0006% mcap100.0% of flowCommon StockSEC:0000950103-26-012874:1
3,411 shares@ US$7.230.0009% mcap8.6% of flowCommon StockSEC:0000950103-26-012875:0
Canonical exit: 19 Nov 2026 (T+90)
5,208 sharesCommon StockSEC:0000950103-26-012874:0
10,184 shares@ US$7.200.0026% mcap3.3% of flowCommon StockSEC:0000950103-26-012870:1
5,208 sharesCommon StockSEC:0000950103-26-012871:0
2,585 shares@ US$7.200.0007% mcap2.4% of flowCommon StockSEC:0000950103-26-012871:1
79,166 shares@ US$1.610.0045% mcap16.7% of flowCommon StockSEC:0000950103-26-012871:2
79,166 shares@ US$7.500.021% mcap78.0% of flowCommon StockSEC:0000950103-26-012871:3
34,658 shares@ US$2.330.0028% mcap6.1% of flowCommon StockSEC:0000950103-26-012872:0
3,647 shares@ US$7.200.0009% mcap2.0% of flowCommon StockSEC:0000950103-26-012872:3
15,342 shares@ US$2.330.0013% mcap2.7% of flowCommon StockSEC:0000950103-26-012872:4
15,342 shares@ US$7.500.0041% mcap8.7% of flowCommon StockSEC:0000950103-26-012872:5
7,291 sharesCommon StockSEC:0000950103-26-012873:0
3,577 shares@ US$7.200.0009% mcap0.9% of flowCommon StockSEC:0000950103-26-012873:1
34,658 shares@ US$7.500.0092% mcap19.6% of flowCommonSEC144:0001959173-26-006346
32,739 shares@ US$6.860.0080% mcap17.1% of flowCommonSEC144:0001959173-26-005704
33,772 shares@ US$2.330.0028% mcap6.0% of flowCommon StockSEC:0000950103-26-011711:0
25 of 261 declarations
About Precigen, Inc.
Precigen, Inc. is a U.S.-based biopharmaceutical company listed on the NASDAQ under the ticker PGEN, with headquarters in Germantown, Maryland, United States. The company originated from Intrexon and has since repositioned itself around precision medicines aimed at difficult-to-treat diseases with high unmet medical need. Its core business is centered on the discovery, development, and commercialization of advanced gene and cell therapy-based products, using proprietary technology designed to address complex biological targets.
For international investors, the most important element of the current equity story is Precigen’s transition from a research-heavy developer into a commercial-stage biopharma company. That shift was driven by the U.S. FDA approval of PAPZIMEOS (zopapogene imadenovec-drba) for adults with recurrent respiratory papillomatosis, or RRP. Recent company communications describe PAPZIMEOS as the first and only FDA-approved therapy for this indication, which gives Precigen a differentiated position in a rare disease niche with significant clinical unmet need. While the company still maintains broader scientific ambitions across immuno-oncology, autoimmune disorders, and infectious diseases, near-term value creation is primarily tied to the commercial rollout of PAPZIMEOS.
Read moreShow less
From a competitive standpoint, Precigen is best viewed as a specialized small-cap biotech rather than a scaled pharmaceutical platform. Its moat is based on scientific differentiation, regulatory exclusivity around its lead asset, and the rarity of the disease area it serves. The company does not compete on breadth of portfolio in the way large-cap pharma does; instead, its investment case depends on clinical credibility, physician adoption, and the ability to translate a novel therapy into sustainable commercial traction. Because it is listed in the United States on NASDAQ, the stock is closely followed by global healthcare investors looking for asymmetric biotech opportunities.
Recent milestones have been material. In August 2025, Precigen received full FDA approval for PAPZIMEOS, and in 2026 the company highlighted expert consensus support and long-term follow-up data that reinforced durable clinical responses. The company has also communicated rapid commercialization momentum in early 2026. Overall, Precigen represents a high-impact healthcare story: a U.S. NASDAQ-listed innovator with one flagship approved product, a clear rare-disease niche, and meaningful execution risk and upside tied to commercial adoption and pipeline progress.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
